#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
This research suggesting CBD and CBG may reduce hepatic steatosis and improve metabolic markers could offer clinicians a potential adjunctive therapeutic option for metabolic-associated fatty liver disease, a condition affecting nearly 25% of the global population with limited pharmacological treatments. Patients with MASLD who fail to respond to lifestyle interventions alone might benefit from evidence-based cannabis compounds, provided future clinical trials establish safety, optimal dosing, and efficacy compared to current standard care. Clinicians should monitor emerging cannabis research on liver disease to counsel informed patients about potential benefits and risks while advocating for regulatory pathways to conduct rigorous human trials.
# Clinical Summary Recent preclinical research demonstrates that cannabidiol (CBD) and cannabigerol (CBG), non-intoxicating cannabis compounds, reduce hepatic lipid accumulation and improve metabolic markers in models of metabolic-associated fatty liver disease (MASLD). The study suggests these cannabinoids may work through pathways that decrease fat synthesis and promote metabolic homeostasis, offering a potential plant-based therapeutic avenue for a disease affecting approximately 25 percent of the global population with limited pharmacologic options. While results are promising at the cellular level, the findings remain preliminary and require rigorous clinical trials to establish safety, efficacy, and optimal dosing in human patients. The work is particularly relevant given that MASLD commonly co-occurs with other metabolic conditions seen in primary care, and patients often seek cannabis-based alternatives when conventional treatments fail or are unavailable. Clinicians should remain informed about emerging cannabis research but should counsel patients that CBD and CBG are not yet established therapies and that any cannabis use requires monitoring for drug interactions, particularly with patients on hepatic medications. For now, clinicians should continue standard MASLD management while noting that controlled clinical trials of purified cannabinoids for this indication could potentially expand treatment options within the next several years.
“What we’re seeing in the metabolic dysfunction-associated fatty liver disease literature is that cannabinoids like CBD and CBG appear to work through multiple pathways simultaneously, reducing hepatic steatosis while improving insulin sensitivity, which is mechanistically distinct from most pharmaceutical approaches we currently have. In my practice, this doesn’t mean I’m recommending cannabis to every patient with fatty liver, but it does mean we should be funding rigorous clinical trials now rather than waiting another decade to understand what could become an important tool in our metabolic disease toolkit.”
🔬 While preclinical findings showing hepatoprotective effects of cannabidiol (CBD) and cannabigerol (CBG) are intriguing, clinicians should recognize that in vitro and animal models often fail to translate to human efficacy and safety. The metabolic benefits observed in controlled laboratory settings may not account for real-world variables such as variable cannabis product quality, drug-drug interactions with hepatic metabolism, potential hepatotoxicity from contaminated products or high doses, and the complex natural history of metabolic dysfunction-associated fatty liver disease (MASLD) in humans. Current evidence is insufficient to recommend cannabis or its isolated compounds as a therapeutic intervention for MASLD outside of clinical trials, and patients should be counseled that whole-plant cannabis use carries risks including impaired metabolic regulation through appetite and movement changes. As research progresses, clinicians caring for patients with MASLD should remain informed about emerging cannabinoid science
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: